Yvonne J. Bryson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yvonne J. Bryson has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Karin Nielsen-Saines
Department of Pediatrics, David Geffen UCLA School of Medicine, Los Angeles, USA
3 shared publications Ruth Dickover
University of California, San Francisco, California,1 University of California, Los Angeles, California,2 National Institute of Allergy and Infectious Diseases, Bethesda, Maryland3
3 shared publicationsEileen Garratty
Department of Pediatrics, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California 90095,1 Los Alamos National Laboratories, Los Alamos, New Mexico 875452
2 shared publicationsEileen M. Garratty
<!--label omitted: 1-->Department of Pediatrics, UCLA School of Medicine, Los Angeles, California
2 shared publications- Jaime G. Deville
David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
2 shared publications Paul Krogstad
Department of Pediatrics, UCLA Children's Hospital, UCLA AIDS Institute, Los Angeles, California
2 shared publications
Latest Publications
- Open Access
Sustained Virologic Suppression Reduces HIV-1 DNA Proviral Levels and HIV Antibodies in Perinatally HIV-Infected Children Followed from Birth
The extent to which perinatally HIV-infected children, following cART initiation, develop a low proviral reservoir burden over time, as measured by HIV DNA droplet-digital polymerase chain reaction (ddPCR) and the effect on HIV antibody is not well characterized. We measured proviral HIV DNA and plasma RNA virus load (VL) in 37 perinatally HIV-infected children at 6 months of age who initiated stable cART. At 6–11 years of age, HIV proviral DNA, HIV VL (RNA), and HIV antibody by Western Blot (WB) were assessed. CART was initiated before 6 months of age in 13 children and after 6 months in 24. At school age, the HIV DNA levels did not differ by the timing of cART, and the HIV DNA levels were lower in children with negative/indeterminate WB (p = 0.0256). Children with undetectable HIV RNA VL > 50% of the time since cART initiation had lower median DNA VL than children with undetectable VL < 50% of the time (p = 0.07). Long-term viral suppression in perinatally HIV-infected children is associated with a decrease in HIV antibodies and reduced HIV reservoirs.
Open AccessSustained Virologic Suppression Reduces HIV-1 DNA Proviral Levels and HIV Antibodies in Perinatally HIV-Infected Children Followed from Birth
The extent to which perinatally HIV-infected children, following cART initiation, develop a low proviral reservoir burden over time, as measured by HIV DNA droplet-digital polymerase chain reaction (ddPCR) and the effect on HIV antibody is not well characterized. We measured proviral HIV DNA and plasma RNA virus load (VL) in 37 perinatally HIV-infected children at 6 months of age who initiated stable cART. At 6–11 years of age, HIV proviral DNA, HIV VL (RNA), and HIV antibody by Western Blot (WB) were assessed. CART was initiated before 6 months of age in 13 children and after 6 months in 24. At school age, the HIV DNA levels did not differ by the timing of cART, and the HIV DNA levels were lower in children with negative/indeterminate WB (p = 0.0256). Children with undetectable HIV RNA VL > 50% of the time since cART initiation had lower median DNA VL than children with undetectable VL < 50% of the time (p = 0.07). Long-term viral suppression in perinatally HIV-infected children is associated with a decrease in HIV antibodies and reduced HIV reservoirs.
- 1 February 2018
- Published by Wolters Kluwer Health in Current Opinion in Pediatrics
- Vol. 30 (1) , 100-104
Advances, innovations, and challenges for new and old infections of children and adolescents
- 1 February 2018
- Published by Wolters Kluwer Health in Current Opinion in Pediatrics
- Vol. 30 (1) , 100-104
Advances, innovations, and challenges for new and old infections of children and adolescents
- 1 February 2016
- Published by Wolters Kluwer Health in Current Opinion in Pediatrics
- Vol. 28 (1) , 79-80
Recent progress and new challenges in pediatric infectious disease
- 1 February 2016
- Published by Wolters Kluwer Health in Current Opinion in Pediatrics
- Vol. 28 (1) , 79-80
Recent progress and new challenges in pediatric infectious disease
- 1 January 2013
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 29 (1) , 77-83
Amniotic Fluid Exhibits an Innate Inhibitory Activity Against HIV Type 1 Replication in Vitro
Indirect evidence suggests that amniotic fluid (AF) may play a role in the pathogenesis of in utero HIV-1 transmission. The purpose of this study was to evaluate the potential innate inhibitory role of AF on HIV replication, which may contribute to protection of the fetus against intrauterine transmission. AF was collected from term HIV-1-negative women undergoing scheduled cesarean section. The inhibitory effect of AF against HIV-1 BA-L replication was tested in vitro with or without the addition of protease inhibitor cocktail (PIC) in PHA-stimulated PBMC cultures. Quantitative measurement of human neutrophil peptides 1-3 (HNP1-3) was performed on all AF samples, using an ELISA assay. AF exhibited a dose-dependent inhibitory activity against HIV-1 BA-L replication, with all samples ( n =12) reaching significant inhibitory effect using 50% AF. In vitro , this activity decreased over time, but was able to be sustained with the addition of PIC. The HNP1-3 concentration in AF samples ( n =12) ranged from undetectable (250,000 pg/ml with a median of 5,146 pg/ml. AF exhibited a significant and dose-dependent innate inhibitory activity against HIV-1 replication, which was present in all AF samples tested. This effect was prolonged in the presence of PIC, suggesting that the inhibitory factor was in the cell-free protein fraction. The HNP1-3 concentration in AF was in the subinhibitory range for HIV with no correlation between its concentration and the HIV-1 inhibitory activity. These data show the presence of a significant innate inhibitory activity against HIV in AF.
- 1 January 2013
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 29 (1) , 77-83
Amniotic Fluid Exhibits an Innate Inhibitory Activity Against HIV Type 1 Replication in Vitro
Indirect evidence suggests that amniotic fluid (AF) may play a role in the pathogenesis of in utero HIV-1 transmission. The purpose of this study was to evaluate the potential innate inhibitory role of AF on HIV replication, which may contribute to protection of the fetus against intrauterine transmission. AF was collected from term HIV-1-negative women undergoing scheduled cesarean section. The inhibitory effect of AF against HIV-1 BA-L replication was tested in vitro with or without the addition of protease inhibitor cocktail (PIC) in PHA-stimulated PBMC cultures. Quantitative measurement of human neutrophil peptides 1-3 (HNP1-3) was performed on all AF samples, using an ELISA assay. AF exhibited a dose-dependent inhibitory activity against HIV-1 BA-L replication, with all samples ( n =12) reaching significant inhibitory effect using 50% AF. In vitro , this activity decreased over time, but was able to be sustained with the addition of PIC. The HNP1-3 concentration in AF samples ( n =12) ranged from undetectable (250,000 pg/ml with a median of 5,146 pg/ml. AF exhibited a significant and dose-dependent innate inhibitory activity against HIV-1 replication, which was present in all AF samples tested. This effect was prolonged in the presence of PIC, suggesting that the inhibitory factor was in the cell-free protein fraction. The HNP1-3 concentration in AF was in the subinhibitory range for HIV with no correlation between its concentration and the HIV-1 inhibitory activity. These data show the presence of a significant innate inhibitory activity against HIV in AF.
- 1 December 2010
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 17 (12) , 2024-2028
Correlation of Immune Activation during Late Pregnancy and Early Postpartum with Increases in Plasma HIV RNA, CD4/CD8 T Cells, and Serum Activation Markers
A previously observed rise in the plasma viral load postpartum in both treated and untreated HIV-positive women remains unexplained. Virological and immunological markers were evaluated in HIV-negative controls and HIV-positive pregnant women with and without antiretroviral treatment. Plasma HIV RNA, CD4/CD8 T cells, and serum activation markers were sequentially measured during the third trimester, at delivery, and 2 to 8 weeks postpartum in a cohort of HIV-positive pregnant women (n= 96) enrolled in a maternal-fetal HIV transmission study and a control group of HIV-negative pregnant women (n= 28). Mean plasma HIV RNA (P= 0.003) increased from delivery to postpartum, and mean CD4 T cells (P= 0.002) and serum β2-microglobulin (P< 0.0001) increased from the third trimester through postpartum among the HIV-positive women. Mean CD8 T cells increased from the third trimester through postpartum in women receiving zidovudine (ZDV) and in those not treated (P< 0.05) but remained stable in those on highly active antiretroviral therapy (HAART) and the HIV-negative controls. Increases in serum β2-microglobulin were correlated with increases in HIV RNA (P= 0.01). HIV-positive pregnant women showed postpartum increases in plasma HIV RNA, CD4 T cells, and serum β2-microglobulin regardless of the treatment regimen. The rise in CD4 T cells and β2-microglobulin was also observed in HIV-negative pregnant women, suggesting hormonal changes and/or labor-induced cytokines may contribute to immune activation. Immune activation correlated with increased plasma HIV RNA in postpartum women despite treatment, although HAART appeared to blunt the effect. The observed rise in plasma HIV RNA postpartum, which correlated with markers of immune activation, may have implications for enhanced transmission to infants through early breast-feeding and to sexual partners.
- 1 December 2010
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 17 (12) , 2024-2028
Correlation of Immune Activation during Late Pregnancy and Early Postpartum with Increases in Plasma HIV RNA, CD4/CD8 T Cells, and Serum Activation Markers
A previously observed rise in the plasma viral load postpartum in both treated and untreated HIV-positive women remains unexplained. Virological and immunological markers were evaluated in HIV-negative controls and HIV-positive pregnant women with and without antiretroviral treatment. Plasma HIV RNA, CD4/CD8 T cells, and serum activation markers were sequentially measured during the third trimester, at delivery, and 2 to 8 weeks postpartum in a cohort of HIV-positive pregnant women (n= 96) enrolled in a maternal-fetal HIV transmission study and a control group of HIV-negative pregnant women (n= 28). Mean plasma HIV RNA (P= 0.003) increased from delivery to postpartum, and mean CD4 T cells (P= 0.002) and serum β2-microglobulin (P< 0.0001) increased from the third trimester through postpartum among the HIV-positive women. Mean CD8 T cells increased from the third trimester through postpartum in women receiving zidovudine (ZDV) and in those not treated (P< 0.05) but remained stable in those on highly active antiretroviral therapy (HAART) and the HIV-negative controls. Increases in serum β2-microglobulin were correlated with increases in HIV RNA (P= 0.01). HIV-positive pregnant women showed postpartum increases in plasma HIV RNA, CD4 T cells, and serum β2-microglobulin regardless of the treatment regimen. The rise in CD4 T cells and β2-microglobulin was also observed in HIV-negative pregnant women, suggesting hormonal changes and/or labor-induced cytokines may contribute to immune activation. Immune activation correlated with increased plasma HIV RNA in postpartum women despite treatment, although HAART appeared to blunt the effect. The observed rise in plasma HIV RNA postpartum, which correlated with markers of immune activation, may have implications for enhanced transmission to infants through early breast-feeding and to sexual partners.
- 1 April 2008
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 9 (2) , 115-125
Pharmacokinetics and Safety of Nelfinavir When Used in Combination with Zidovudine and Lamivudine in HIV-Infected Pregnant Women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353
Background: Combination antiretroviral regimens including nelfinavir (NFV) are commonly used in pregnancy. We studied the safety, antiviral effect, and pharmacokinetics of NFV and its M8 metabolite with two dosing regimens in combination with zidovudine (ZDV) and lamivudine (3TC) in HIV-infected pregnant women. Method: HIV-infected pregnant women between 14 and 34 weeks gestation received NFV (Cohort 1: 750 mg tid, n = 10; Cohort 2: 1250 mg bid, n = 23) with ZDV and 3TC. Serial blood sampling for NFV concentrations was performed antepartum (AP) and 6 weeks postpartum (PP). Maternal and cord blood samples were also obtained at delivery. NFV and M8 levels were determined by high-performance liquid chromatography. The pharmacokinetic (PK) target was an extrapolated NFV AUC0–24 > 30 μg · h/mL. Mothers were followed frequently for potential clinical and laboratory toxicity. Results: Overall, NFV in combination with ZDV and 3TC was well tolerated. The PK target was met in 3/8 AP and 5/7 PP in Cohort 1 and 17/21 AP and 16/17 PP in Cohort 2. When Cohort 2 NFV PK parameters AP and PP were compared, median Cmax (3.90 μg/mL vs. 5.01 μg/mL, p < .05) and AUC0-24 (56.6 vs. 86.8 μg · h/mL, p < .05) were increased PP and oral clearance (Cl/F; 44.2 vs. 28.8 L/h, p < .05) was decreased PP. The average M8/NFV ratio was increased PP compared to AP (0.085 vs. 0.29, p < .001). Placental transfer of NFV was low with a median cord blood:maternal plasma ratio at delivery of 0.05. Maternal mean CD4+ T cell counts increased significantly and plasma HIV-1 RNA levels decreased from entry to delivery and 6 to 12 weeks postpartum. Conclusion: NFV used in combination with ZDV and 3TC was well tolerated in pregnant HIV-infected women and produced a significant improvement in HIV disease parameters. NFV drug exposure is inadequate in most pregnant women receiving 750 mg tid but is much improved with 1250 mg bid. NFV crosses the placenta poorly. The AP increase in NFV oral clearance and decrease in M8/NFV ratio suggest that CYP3A activity increases relative to CYP2C19 activity during pregnancy.
- 1 April 2008
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 9 (2) , 115-125
Pharmacokinetics and Safety of Nelfinavir When Used in Combination with Zidovudine and Lamivudine in HIV-Infected Pregnant Women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353
Background: Combination antiretroviral regimens including nelfinavir (NFV) are commonly used in pregnancy. We studied the safety, antiviral effect, and pharmacokinetics of NFV and its M8 metabolite with two dosing regimens in combination with zidovudine (ZDV) and lamivudine (3TC) in HIV-infected pregnant women. Method: HIV-infected pregnant women between 14 and 34 weeks gestation received NFV (Cohort 1: 750 mg tid, n = 10; Cohort 2: 1250 mg bid, n = 23) with ZDV and 3TC. Serial blood sampling for NFV concentrations was performed antepartum (AP) and 6 weeks postpartum (PP). Maternal and cord blood samples were also obtained at delivery. NFV and M8 levels were determined by high-performance liquid chromatography. The pharmacokinetic (PK) target was an extrapolated NFV AUC0–24 > 30 μg · h/mL. Mothers were followed frequently for potential clinical and laboratory toxicity. Results: Overall, NFV in combination with ZDV and 3TC was well tolerated. The PK target was met in 3/8 AP and 5/7 PP in Cohort 1 and 17/21 AP and 16/17 PP in Cohort 2. When Cohort 2 NFV PK parameters AP and PP were compared, median Cmax (3.90 μg/mL vs. 5.01 μg/mL, p < .05) and AUC0-24 (56.6 vs. 86.8 μg · h/mL, p < .05) were increased PP and oral clearance (Cl/F; 44.2 vs. 28.8 L/h, p < .05) was decreased PP. The average M8/NFV ratio was increased PP compared to AP (0.085 vs. 0.29, p < .001). Placental transfer of NFV was low with a median cord blood:maternal plasma ratio at delivery of 0.05. Maternal mean CD4+ T cell counts increased significantly and plasma HIV-1 RNA levels decreased from entry to delivery and 6 to 12 weeks postpartum. Conclusion: NFV used in combination with ZDV and 3TC was well tolerated in pregnant HIV-infected women and produced a significant improvement in HIV disease parameters. NFV drug exposure is inadequate in most pregnant women receiving 750 mg tid but is much improved with 1250 mg bid. NFV crosses the placenta poorly. The AP increase in NFV oral clearance and decrease in M8/NFV ratio suggest that CYP3A activity increases relative to CYP2C19 activity during pregnancy.
- 1 June 2007
- Published by Springer Nature in Pediatric Research
- Vol. 61 (6) , 692-697
Pediatric HIV-1–Specific Cytotoxic T-Lymphocyte Responses Suggesting Ongoing Viral Replication Despite Combination Antiretroviral Therapy
- 1 June 2007
- Published by Springer Nature in Pediatric Research
- Vol. 61 (6) , 692-697
Pediatric HIV-1–Specific Cytotoxic T-Lymphocyte Responses Suggesting Ongoing Viral Replication Despite Combination Antiretroviral Therapy
- 1 July 2006
- Published by American Society for Microbiology in Journal of Virology
- Vol. 80 (13) , 6525-6533
Role of Maternal Autologous Neutralizing Antibody in Selective Perinatal Transmission of Human Immunodeficiency Virus Type 1 Escape Variants
Perinatal human immunodeficiency virus type 1 (HIV-1) transmission is characterized by acquisition of a homogeneous viral quasispecies, yet the selective factors responsible for this genetic bottleneck are unclear. We examined the role of maternal autologous neutralizing antibody (aNAB) in selective transmission of HIV-1 escape variants to infants. Maternal sera from 38 infected mothers at the time of delivery were assayed for autologous neutralizing antibody activity against maternal time-of-delivery HIV-1 isolates in vitro. Maternal sera were also tested for cross-neutralization of infected-infant-first-positive-time-point viral isolates. Heteroduplex and DNA sequence analyses were then performed to identify the initial infecting virus as a neutralization-sensitive or escape HIV-1 variant. In utero transmitters ( n = 14) were significantly less likely to have aNAB to their own HIV-1 strains at delivery than nontransmitting mothers ( n = 17, 14.3% versus 76.5%, P = 0.003). Cross-neutralization assays of infected-infant-first-positive-time-point HIV-1 isolates indicated that while 14/21 HIV-1-infected infant first positive time point isolates were resistant to their own mother's aNAB, no infant isolate was inherently resistant to antibody neutralization by all sera tested. Furthermore, both heteroduplex ( n = 21) and phylogenetic ( n = 9) analyses showed that selective perinatal transmission and/or outgrowth of maternal autologous neutralization escape HIV-1 variants occurs in utero and intrapartum. These data indicate that maternal autologous neutralizing antibody can exert powerful protective and selective effects in perinatal HIV-1 transmission and therefore has important implications for vaccine development.
- 1 July 2006
- Published by American Society for Microbiology in Journal of Virology
- Vol. 80 (13) , 6525-6533
Role of Maternal Autologous Neutralizing Antibody in Selective Perinatal Transmission of Human Immunodeficiency Virus Type 1 Escape Variants
Perinatal human immunodeficiency virus type 1 (HIV-1) transmission is characterized by acquisition of a homogeneous viral quasispecies, yet the selective factors responsible for this genetic bottleneck are unclear. We examined the role of maternal autologous neutralizing antibody (aNAB) in selective transmission of HIV-1 escape variants to infants. Maternal sera from 38 infected mothers at the time of delivery were assayed for autologous neutralizing antibody activity against maternal time-of-delivery HIV-1 isolates in vitro. Maternal sera were also tested for cross-neutralization of infected-infant-first-positive-time-point viral isolates. Heteroduplex and DNA sequence analyses were then performed to identify the initial infecting virus as a neutralization-sensitive or escape HIV-1 variant. In utero transmitters ( n = 14) were significantly less likely to have aNAB to their own HIV-1 strains at delivery than nontransmitting mothers ( n = 17, 14.3% versus 76.5%, P = 0.003). Cross-neutralization assays of infected-infant-first-positive-time-point HIV-1 isolates indicated that while 14/21 HIV-1-infected infant first positive time point isolates were resistant to their own mother's aNAB, no infant isolate was inherently resistant to antibody neutralization by all sera tested. Furthermore, both heteroduplex ( n = 21) and phylogenetic ( n = 9) analyses showed that selective perinatal transmission and/or outgrowth of maternal autologous neutralization escape HIV-1 variants occurs in utero and intrapartum. These data indicate that maternal autologous neutralizing antibody can exert powerful protective and selective effects in perinatal HIV-1 transmission and therefore has important implications for vaccine development.
- 1 July 2001
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 3 (4) , 388-396
Perinatal transmission of HIV: Recognition and treatment interventions
Great strides have been made in the fight against vertical transmission of HIV-1. Improved understanding of mechanisms and timing of transmission of HIV-1 from mother to child have led to the development of effective intervention strategies that have reduced transmission rates to unprecedented low levels, below 2% in developed countries. New reports using shortened, more affordable courses of antiretrovirals prenatally or at the time of delivery have also shown a significant reduction in transmission, over 50% in studies conducted in the developing world. These advances, combined with ongoing studies using simplified effective treatment regimens, have made possible the potential to significantly reduce perinatal transmission worldwide. Future challenges include reduction of breast feeding transmission and the development of an effective HIV-1 vaccine to produce long-lasting protection.
- 1 July 2001
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 3 (4) , 388-396
Perinatal transmission of HIV: Recognition and treatment interventions
Great strides have been made in the fight against vertical transmission of HIV-1. Improved understanding of mechanisms and timing of transmission of HIV-1 from mother to child have led to the development of effective intervention strategies that have reduced transmission rates to unprecedented low levels, below 2% in developed countries. New reports using shortened, more affordable courses of antiretrovirals prenatally or at the time of delivery have also shown a significant reduction in transmission, over 50% in studies conducted in the developing world. These advances, combined with ongoing studies using simplified effective treatment regimens, have made possible the potential to significantly reduce perinatal transmission worldwide. Future challenges include reduction of breast feeding transmission and the development of an effective HIV-1 vaccine to produce long-lasting protection.